Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Uridine Triacetate · Vistogard, Xuriden

Small molecule · developed by Btg Intl

Approved FDA, Sep 2015
1 Registered trials

What is Uridine Triacetate?

Uridine triacetate is an oral acetylated pro-drug of uridine that is deacetylated in the body to yield uridine in the circulation. Uridine competes with the fluorouracil metabolite FUTP for incorporation into RNA and thereby reduces fluorouracil cytotoxicity. It is studied in mitochondrial diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Vistogard, Xuriden, RG-2133, PN-401
Drug type
Small molecule
Pathways
pyrimidine nucleotide metabolism, RNA incorporation of fluorouracil metabolite (FUTP), thymidylate synthase-mediated DNA synthesis
Therapy area
Metabolic
Developer
Btg Intl
In trials of
RGEN
FDA status
Approved as Vistogard, Xuriden (September 4, 2015), NDA208169 · FDA label
UNII
2WP61F175M

✅ FDA-approved uses

From the indications section of the FDA label (version of Mar 31, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00060515 Phase 1 Mitochondrial Diseases Terminated RGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mitochondrial Diseases

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.